Explore jobs
Find specific jobs
Explore careers
Explore professions
Best companies
Explore companies
CoolSculpting history
CoolSculpting company history timeline
He also served as Abbott’s President and Chief Operating Officer, prior to a brief retirement in 2007.
Drugwatch.com has provided reliable, trusted information about medications, medical devices and general health since 2008.
Abbott acquired Solvay’s pharmaceutical division in 2010 and took on Marinol as well.
On October 19, 2011, Abbott Laboratories announced that it planned to separate into two publicly traded companies, one focused on diversified medical products and the other on research-based pharmaceuticals.
The company was founded on April 10, 2012, and is headquartered in North Chicago, IL.”
What started in 2014 as a primarily headquarters-based week of service involving a thousand employees, has since become a global AbbVie tradition with more than 7,000 employees in nearly 60 countries.
Humira was the world’s top-selling prescription drug in 2015, according to The New York Times.
March 2016 AbbVie gains new approvals for Imbruvica and Venclexta/Venclyxto
June 2016 FDA approves Humira to treat an immune-mediated disease that can impair vision
Helfand, C. (2018, March 7). EMA suspends, recalls AbbVie and Biogen’s doomed MS drug Zinbryta.
The middle school capped off our $350 million nonprofit charitable contribution pledge in 2018 and built on our longstanding commitment to investing in North Chicago.
June 2019 AbbVie and Allergan announce that the companies have entered into a definitive transaction agreement under which AbbVie will acquire Allergan
On May 8, 2020, the United States pharmaceutical company AbbVie acquired Allergan for $63 billion, and return Allergan to the United States for tax purposes.
© 2022 Drugwatch.com Privacy Policy / Advertising Disclosure / Do Not Sell My Info
Rate how well CoolSculpting lives up to its initial vision.
CoolSculpting jobs
Do you work at CoolSculpting?
Does CoolSculpting communicate its history to new hires?
CoolSculpting competitors
| Company name | Founded date | Revenue | Employee size | Job openings |
|---|---|---|---|---|
| NuVasive | 1997 | $1.2B | 2,800 | 22 |
| Seagen | 1997 | $2.0B | 900 | - |
| Hospira | 2004 | $4.5B | 19,000 | - |
| Cepheid | 1996 | $531.1M | 6,000 | - |
| Merck | 1891 | $64.2B | 74,000 | 1,485 |
| Intersect ENT | 2003 | $106.7M | 393 | - |
| Gilead Sciences | 1987 | $28.8B | 11,800 | 845 |
| Sarepta Therapeutics | 1980 | $1.9B | 840 | 22 |
| Neurocrine Biosciences | 1992 | $2.4B | 400 | 335 |
| Sciton | 1997 | $17.0M | 300 | 23 |
CoolSculpting history FAQs
Zippia gives an in-depth look into the details of CoolSculpting, including salaries, political affiliations, employee data, and more, in order to inform job seekers about CoolSculpting. The employee data is based on information from people who have self-reported their past or current employments at CoolSculpting. The data on this page is also based on data sources collected from public and open data sources on the Internet and other locations, as well as proprietary data we licensed from other companies. Sources of data may include, but are not limited to, the BLS, company filings, estimates based on those filings, H1B filings, and other public and private datasets. While we have made attempts to ensure that the information displayed are correct, Zippia is not responsible for any errors or omissions or for the results obtained from the use of this information. None of the information on this page has been provided or approved by CoolSculpting. The data presented on this page does not represent the view of CoolSculpting and its employees or that of Zippia.
CoolSculpting may also be known as or be related to ZELTIQ Aesthetics, Inc., Zeltiq, CoolSculpting, Zeltiq Aesthetics, Inc., ZELTIQ AESTHETICS INC and ZELTIQ Aesthetics Inc.